45 CFR § 180 compliance
B · 85
This hospital published most of what § 180 requires.
●Machine-readable file published
●Gross / standard charges
●Discounted cash price
●Payer-specific negotiated rates
○Min / max negotiated charges
●Free, public, no login required
Procedures listed
9,726
Insurances with rates
21
CPT / HCPCS codes
0
Source MRF
Most expensive procedures (gross)
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| 124600036 | INJECTION, IPILIMUMAB, 1 MG | $88,668 | $66,501 | — | — | 22 |
| 125000375 | INJECTION, RISANKIZUMAB-RZAA, INTRAVENOUS, 1 MG | $74,000 | $55,500 | — | — | 21 |
| 125000274 | USTEKINUMAB, FOR SUBCUTANEOUS INJECTION, 1 MG | $70,629 | $52,972 | — | — | 22 |
| 124200137 | INJECTION, LONCASTUXIMAB TESIRINE-LPYL, 0.075 MG | $69,566 | $52,175 | — | — | 21 |
| 125000373 | INJECTION, OCRELIZUMAB, 1 MG | $51,665 | $38,749 | — | — | 22 |
| 124200159 | INJECTION, POLATUZUMAB VEDOTIN-PIIQ, 1 MG | $43,965 | $32,974 | — | — | 22 |
| 124200130 | NOT OTHERWISE CLASSIFIED, ANTINEOPLASTIC DRUGS | $42,142 | $31,607 | — | — | 22 |
| 124200146 | INJECTION, EFGARTIGIMOD ALFA, 2 MG AND HYALURONIDASE-QVFC | $41,062 | $30,797 | — | — | 21 |
| 125001114 | JOINT DEVICE (IMPLANTABLE) | $40,000 | $30,000 | — | — | 22 |
| 125000602 | INJECTION, IMETELSTAT, 1 MG | $37,000 | $27,750 | — | — | 21 |
| 124200153 | INJECTION, PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF, PER 10 MG | $35,793 | $26,845 | — | — | 22 |
| 124200154 | INJECTION, PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF, PER 10 MG | $35,793 | $26,845 | — | — | 22 |
| 125000506 | INJECTION, GUSELKUMAB, 1 MG | $34,101 | $25,576 | — | — | 22 |
| 125000579 | INJECTION, LUSPATERCEPT-AAMT, 0.25 MG | $30,917 | $23,188 | — | — | 22 |
| 124600039 | LEUPROLIDE ACETATE (FOR DEPOT SUSPENSION), 7.5 MG | $30,182 | $22,636 | — | — | 22 |
| 125000046 | INJECTION, ATEZOLIZUMAB, 10 MG | $28,982 | $21,737 | — | — | 22 |
| 125000019 | INJECTION, CEMIPLIMAB-RWLC, 1 MG | $28,977 | $21,733 | — | — | 22 |
| 123800234 | ALLODERM, PER SQUARE CENTIMETER | $28,707 | $21,530 | — | — | 22 |
| 124600002 | INJECTION, NIVOLUMAB, 2 MG AND HYALURONIDASE-NVHY | $28,000 | $21,000 | — | — | 21 |
| 125000374 | INJECTION, UBLITUXIMAB-XIIY, 1MG | $27,583 | $20,687 | — | — | 21 |
| 125001220 | JOINT DEVICE (IMPLANTABLE) | $27,500 | $20,625 | — | — | 22 |
| 126900152 | ANCHOR/SCREW FOR OPPOSING BONE-TO-BONE OR SOFT TISSUE-TO-BONE (IMPLANTABLE) | $27,300 | $20,475 | — | — | 22 |
| 125000376 | INJECTION, RISANKIZUMAB-RZAA, INTRAVENOUS, 1 MG | $25,785 | $19,339 | — | — | 21 |
| 125000302 | INJECTION, ALTEPLASE RECOMBINANT, 1 MG | $25,636 | $19,227 | — | — | 22 |
| 125001315 | GENERATOR, NEUROSTIMULATOR (IMPLANTABLE), NON-RECHARGEABLE | $24,459 | $18,344 | — | — | 22 |
| 124200147 | INJECTION, PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF, PER 10 MG | $23,918 | $17,939 | — | — | 22 |
| 1270005868 | PM0003935 MANGINA TRIFLNG SZ23 | $23,875 | $17,906 | — | — | 20 |
| 125000017 | INJECTION, DARATUMUMAB, 10 MG AND HYALURONIDASE-FIHJ | $23,579 | $17,684 | — | — | 22 |
| 124600037 | INJECTION, IPILIMUMAB, 1 MG | $22,991 | $17,243 | — | — | 22 |
| 125000378 | INJECTION, NATALIZUMAB, 1 MG | $21,501 | $16,126 | — | — | 22 |
| 124200157 | INJECTION, RITUXIMAB 10 MG AND HYALURONIDASE | $20,838 | $15,629 | — | — | 22 |
| 111200012 | INJECTION, LURBINECTEDIN, 0.1 MG | $20,769 | $15,577 | — | — | 22 |
| 116000192 | Complete laser vaporization of prostate including control of bleeding using an endoscope | $20,172 | $15,129 | — | — | 22 |
| 125000541 | INJECTION, ETANERCEPT, 25 MG (CODE MAY BE USED FOR MEDICARE WHEN DRUG ADMINISTERED UNDER THE DIRECT | $20,034 | $15,026 | — | — | 22 |
| 125000832 | MESH (IMPLANTABLE) | $19,000 | $14,250 | — | — | 22 |
| 125001208 | JOINT DEVICE (IMPLANTABLE) | $18,953 | $14,215 | — | — | 22 |
| 124200161 | INJECTION, RAMUCIRUMAB, 5 MG | $18,459 | $13,844 | — | — | 22 |
| 124400012 | INJECTION, OBINUTUZUMAB, 10 MG | $18,347 | $13,760 | — | — | 22 |
| 125000372 | INJECTION, OCTREOTIDE, DEPOT FORM FOR INTRAMUSCULAR INJECTION, 1 MG | $18,104 | $13,578 | — | — | 22 |
| 125001372 | CATHETER, BALLOON DILATATION, NON-VASCULAR | $17,125 | $12,844 | — | — | 22 |
| 123000017 | Shock wave crushing of kidney stones | $16,873 | $12,655 | — | — | 21 |
| 125001225 | JOINT DEVICE (IMPLANTABLE) | $16,750 | $12,563 | — | — | 22 |
| 125000254 | INJECTION, VEDOLIZUMAB, INTRAVENOUS, 1 MG | $16,695 | $12,521 | — | — | 22 |
| 124200142 | INJECTION, TRASTUZUMAB, 10 MG AND HYALURONIDASE-OYSK | $16,500 | $12,375 | — | — | 22 |
| 125000974 | JOINT DEVICE (IMPLANTABLE) | $16,131 | $12,098 | — | — | 22 |
| 1270005769 | ANCHOR/SCREW FOR OPPOSING BONE-TO-BONE OR SOFT TISSUE-TO-BONE (IMPLANTABLE) | $15,860 | $11,895 | — | — | 22 |
| 124600041 | LEUPROLIDE ACETATE (FOR DEPOT SUSPENSION), 7.5 MG | $15,805 | $11,854 | — | — | 22 |
| 125000293 | INJECTION, TENECTEPLASE, 1 MG | $15,330 | $11,498 | — | — | 22 |
| 125001015 | JOINT DEVICE (IMPLANTABLE) | $15,200 | $11,400 | — | — | 22 |
| 124600007 | INJECTION, PEMBROLIZUMAB, 1 MG | $15,195 | $11,396 | — | — | 22 |
Showing top 50 of 9,726 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.